(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted one of its private portfolio companies Evommune Inc raised USD150 million in its initial public offering. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday confirmed it has entered into a royalty funding agreement with clinical stage biopharmaceutical company Savara Inc for a rare lung disease treatment. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted that Swiss pharmaceutical major Novartis AG has definitively agreed to buy portfolio company Avidity Biosciences Inc. Read More
RTW Biotech Opportunities Ltd - Guernsey-based investor in life sciences sector - Adds USD15 million to share buyback programme, aiming to close the discount of its share price to net asset value. RTW Biotech has USD5.8 million to complete from its current USD30 million buyback and will top that up by USD15 million, which is equivalent to about 9.2 million shares. Funds for the buyback come from several recent realisations of portfolio holdings. The company's most recently report net asset value, as of June 30, was USD1.70. Read More
(Alliance News) - RTW Biotech Opportunities Ltd said on Wednesday that it invested USD7.4 million in Kailera Therapeutics Inc for the company's USD600 million Series B financing round. Read More
(Alliance News) - Akero Therapeutics Inc on Friday said it will benefit from "industry-leading development capabilities and commercial infrastructure" through its acquisition by Novo Nordisk AS. Read More
RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Notes Biogen Inc's agreement announced last Thursday to acquire portfolio company Alcyone Therapeutics Inc for USD85 million upfront plus milestone payments. Says the deal represents a 242% uplift on RTW's USD2.1 million carrying value of Alcyone, adding USD5.0 million, or around 0.7%, to its August 31 NAV, where Alcyone represented approximately a 0.3% position. Alcyone is developing ThecaFlex DRx, an implantable device for intrathecal delivery of neurological therapies, which Biogen plans to deploy with its marketed drug Spinraza, with a launch targeted in 2028. The transaction its RTW's second portfolio takeout this year, following Merck & Co Inc's purchase of Verona Pharma PLC, and says it highlights embedded value in its private holdings. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said the biotech industry is navigating a "complex but increasingly constructive environment" as it reported a decline in its interim net asset value per share. Read More
RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Says it will join the FTSE all-share index on September 22. This follows FTSE Russell's decision to include securities trading in non-sterling currencies. Chair William Simpson says the move "is likely to enhance our exposure to investors, develop greater UK and international investor awareness of RTW Bio, and provide increased long-term access to capital." Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday noted Aquestive Therapeutics Inc's announcement of a strategic funding agreement with funds managed by RTW Investments LP. Read More
(Alliance News) - Merck & Co Inc on Wednesday said it has struck a deal to acquire Verona Pharma PLC, bolstering its respiratory diseases offering. Read More
(Alliance News) - Water utility Severn Trent and housebuilder Vistry backed guidance, while advertising firm WPP named a new chief executive. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday highlighted clinical developments from Corxel Pharmaceuticals (Shanghai) Co Ltd, its second-largest portfolio holding, including the start of a US phase 2 trial and positive results from a China study of Corxel's lead obesity treatment, CX11. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday provided updates on three of its key listed holdings, highlighting both promising clinical trial results and a significant setback involving one of its biotech investments. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted investee Rocket Pharmaceuticals has reported "encouraging" data from a phase 1 clinical trial of its treatment for arrhythmogenic cardiomyopathy. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted positive trial data from investee Artios Pharma, for the ongoing study of its lead candidate ART0380. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced a new investment into biotech company Airna, closing its oversubscribed USD155 million series B financing round. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said it underperformed its benchmarks during 2024, while total net asset value climbed following the takeover of Arix Bioscience PLC. Read More